CA2701537A1 - Compositions for treatment of tumors by direct administration of a radioisotope - Google Patents

Compositions for treatment of tumors by direct administration of a radioisotope Download PDF

Info

Publication number
CA2701537A1
CA2701537A1 CA2701537A CA2701537A CA2701537A1 CA 2701537 A1 CA2701537 A1 CA 2701537A1 CA 2701537 A CA2701537 A CA 2701537A CA 2701537 A CA2701537 A CA 2701537A CA 2701537 A1 CA2701537 A1 CA 2701537A1
Authority
CA
Canada
Prior art keywords
radioisotope
composition
bone
administration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2701537A
Other languages
English (en)
French (fr)
Inventor
R. Keith Frank
Kenneth Mcmillan
Jaime Simon
H. Max Loy
Stanley D. Stearns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GABRIEL INSTITUTE Inc
IsoTherapeutics Group LLC
Original Assignee
Isotherapeutics Group Llc
R. Keith Frank
Kenneth Mcmillan
Jaime Simon
H. Max Loy
Stanley D. Stearns
Gabriel Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotherapeutics Group Llc, R. Keith Frank, Kenneth Mcmillan, Jaime Simon, H. Max Loy, Stanley D. Stearns, Gabriel Institute, Inc. filed Critical Isotherapeutics Group Llc
Publication of CA2701537A1 publication Critical patent/CA2701537A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2701537A 2007-10-05 2008-02-15 Compositions for treatment of tumors by direct administration of a radioisotope Abandoned CA2701537A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99785607P 2007-10-05 2007-10-05
US99787307P 2007-10-05 2007-10-05
US60/997,873 2007-10-05
US60/997,856 2007-10-05
PCT/US2008/002026 WO2009045230A1 (en) 2007-10-05 2008-02-15 Compositions for treatment of tumors by direct administration of a radioisotope

Publications (1)

Publication Number Publication Date
CA2701537A1 true CA2701537A1 (en) 2009-04-09

Family

ID=40526495

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701537A Abandoned CA2701537A1 (en) 2007-10-05 2008-02-15 Compositions for treatment of tumors by direct administration of a radioisotope

Country Status (4)

Country Link
EP (1) EP2195036A4 (de)
JP (1) JP2010540627A (de)
CA (1) CA2701537A1 (de)
WO (1) WO2009045230A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008232A2 (en) 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
DOP2010000279A (es) * 2009-09-18 2012-06-15 Sari Asher Llc Composiciones radiofarmaceuticas no-coloidales sin sellar y metodos para el tratamiento de tejido anormal
US9437336B2 (en) 2010-03-09 2016-09-06 Kurion, Inc. Isotope-specific separation and vitrification using ion-specific media
US9365911B2 (en) 2012-03-26 2016-06-14 Kurion, Inc. Selective regeneration of isotope-specific media resins in systems for separation of radioactive isotopes from liquid waste materials
GB2490317A (en) * 2011-04-19 2012-10-31 Dspi Ltd Radioactive solution undergoing in situ precipitation at a tumour site for cancer therapy
ES2671622T3 (es) * 2011-12-21 2018-06-07 Iso Therapeutics Group Llc Composiciones y métodos radiactivos para su uso terapéutico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849209A (en) * 1985-06-07 1989-07-18 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
US4915932A (en) * 1987-10-14 1990-04-10 Australian Nuclear Science & Technology Organisation Macroaggregates for radiation synovectomy
EP1610751A4 (de) * 2001-04-26 2006-05-24 Univ Texas Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
AU2003299565A1 (en) * 2002-11-27 2004-06-23 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
CA2579612A1 (en) * 2004-09-24 2006-04-06 Biosphere Medical, Inc. Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof

Also Published As

Publication number Publication date
JP2010540627A (ja) 2010-12-24
EP2195036A4 (de) 2011-03-09
EP2195036A1 (de) 2010-06-16
WO2009045230A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
ES2268888T3 (es) El uso de radio-223 para dirigirse a tejidos calcificados para paliacion del dolor y terapia de cancer oseo.
Farhanghi et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer
JP5219325B2 (ja) 骨標的錯体
US10918746B2 (en) Radioactive compositions and methods for their therapeutic use
AU2001267734A1 (en) Radiotherapy
CA2701537A1 (en) Compositions for treatment of tumors by direct administration of a radioisotope
WO2011149844A1 (en) Delivery of high dose therapeutic radioisotopes to bone
US20120251442A1 (en) Methods for Treatment of Tumors by Direct Administration of a Radioisotope
US20090252675A1 (en) Radionuclide Therapy for Urinary Bladder Cancer
US8709380B1 (en) Targeting agents for enhancing radiation therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150317